FILOMENA COLELLA

Dr. FILOMENA COLELLA

Università Cattolica del Sacro Cuore, Roma
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DLDonatella Lucchetti
Donatella Lucchetti
CTClaudio Ricciardi Tenore
Claudio Ricciardi Tenore
FCFILOMENA COLELLA
FILOMENA COLELLA
ASAlessandro Sgambato
Alessandro Sgambato
A better understanding of the mechanisms of cell communication between cancer cells and the tumor microenvironment is crucial to develop personalized therapies. It has been known for a while that cancer cells are metabolically distinct from other non-transformed cells. This metabolic phenotype is not peculiar to cancer cells but reflects the characteristics of the tumor microenvironment. Recently, it has been shown that extracellular vesicles are involved in the metabolic switch occurring in cancer and tumor-stroma cells. Moreover, in an immune system, the metabolic programs of different cell subsets are distinctly associated with their immunological function, and extracellular vesicles could be a key factor in the shift of cell fate modulating cancer immunity. Indeed, during tumor progression, tumor-associated immune cells and fibroblasts acquire a tumor-supportive and anti-inflammatory phenotype due to their interaction with tumor cells and several findings suggest a role of extracellular vesicles in this phenomenon. This review aims to collect all the available evidence so far obtained on the role of extracellular vesicles in the modulation of cell metabolism and immunity. Moreover, we discuss the possibility for extracellular vesicles of being involved in drug resistance mechanisms, cancer progression and metastasis by inducing immune-metabolic effects on surrounding cells.

Verified
Journal Article
Open access
PDF file
DLDonatella Lucchetti
Donatella Lucchetti
ABAlessandra Battaglia
Alessandra Battaglia
CTClaudio Ricciardi Tenore
Claudio Ricciardi Tenore
FCFILOMENA COLELLA
FILOMENA COLELLA
LPLuigi Perelli
Luigi Perelli
AFAndrea Fattorossi
Andrea Fattorossi
Intense research is being conducted using flow cytometers available in clinically oriented laboratories to assess extracellular vesicles (EVs) surface cargo in a variety of diseases. Using EVs of various sizes purified from the HT29 human colorectal adenocarcinoma cell line, we report on the difficulty to assess small and medium sized EVs by conventional flow cytometer that combines light side scatter off a 405 nm laser with the fluorescent signal from the EVs general labels Calcein-green and Calcein-violet, and surface markers. Small sized EVs (~70 nm) immunophenotyping failed, consistent with the scarcity of monoclonal antibody binding sites, and were therefore excluded from further investigation. Medium sized EVs (~250 nm) immunophenotyping was possible but their detection was plagued by an excess of coincident particles (swarm detection) and by a high abort rate; both factors affected the measured EVs concentration. By running samples containing equal amounts of Calcein-green and Calcein-violet stained medium sized EVs, we found that swarm detection produced false double positive events, a phenomenon that was significantly reduced, but not totally eliminated, by sample dilution. Moreover, running highly diluted samples required long periods of cytometer time. Present findings raise questions about the routine applicability of conventional flow cytometers for EV analysis.

21 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DLDonatella Lucchetti
Donatella Lucchetti
FCFILOMENA COLELLA
FILOMENA COLELLA
LPLuigi Perelli
Luigi Perelli
CTClaudio Ricciardi Tenore
Claudio Ricciardi Tenore
FCFederica Calapà
Federica Calapà
ASAlessandro Sgambato
Alessandro Sgambato
Cancer cells secrete small extracellular vesicles (sEVs) that are involved in the remodeling of tumor microenvironment (TME) and can promote tumor progression. The role of sEVs and their molecular key players in colon cancer stem cells differentiation are poorly understood. This study aimed to analyze the role and content of sEVs released during the differentiation of colorectal cancer stem cells. Here we show that sEVs secretion during colon cancer stem cells differentiation is partially controlled by CD147, a well-known player involved in colon cancer tumorigenesis. CD147 + sEVs activate a signaling cascade in recipient cells inducing molecular invasive features in colon cancer cells. CD147 knockdown as well as anti-CD147 antibodies impaired sEVs release and downstream effects on recipient cells and blocking multivesicular body maturation prevented sEVs release during the differentiation. Our findings reveal a functional role of CD147 in promoting sEVs release during the differentiation of colon cancer stem cells and in triggering cellular changes in recipient cells.

1 October 2019 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
CFC. De Fino
C. De Fino
MLM. Lucchini
M. Lucchini
DLD. Lucchetti
D. Lucchetti
VNV. Nociti
V. Nociti
FLF.A. Losavio
F.A. Losavio
MMMassimiliano Mirabella
Massimiliano Mirabella

22 January 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
DLDonatella Lucchetti
Donatella Lucchetti
LPLuigi Perelli
Luigi Perelli
FCFILOMENA COLELLA
FILOMENA COLELLA
CRClaudio Ricciardi‐Tenore
Claudio Ricciardi‐Tenore
GSGian Luca Scoarughi
Gian Luca Scoarughi
ASAlessandro Sgambato
Alessandro Sgambato

16 April 2025 in Laboratory Investigation
Verified
Journal Article
Closed access
DLDonatella Lucchetti
Donatella Lucchetti
FCFILOMENA COLELLA
FILOMENA COLELLA
ADAntonio D’AMati
Antonio D’AMati
TSTiziana Servidei
Tiziana Servidei
MGMarco Gessi
Marco Gessi
ASAlessandro Sgambato
Alessandro Sgambato